Phaseline

Targets › GAA

GAA (Lysosomal alpha-glucosidase): drug programs, companies and trials

6 programs from 6 companies in 11 trials: 5 Phase 1, 3 Phase 4, 2 Phase 3, 1 Phase 2; Metabolic and endocrine; next expected readout Dec 2026.

Essential for the degradation of glycogen in lysosomes. Has highest activity on alpha-1,4-linked glycosidic linkages, but can also hydrolyze alpha-1,6-linked glucans. (UniProt, P10253)

Open in Phaseline: the race on GAA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
SanofiAvalglucosidase alfa (GZ402666)
Lysosomal acid alpha-glucosidase (GAA) replacement therapy
GAAPhase 4Glycogen Storage Disease Type II; Glycogen Storage Disease Type II-Pompe's Disease; Glycogen Storage Disease Type II Late OnsetJun 2027
Amicus TherapeuticsCipaglucosidase Alfa (ATB200)
Acid alpha-glucosidase (GAA) enzyme replacement therapy
GAAPhase 3Pompe Disease (Late-onset); Glycogen Storage Disease Type II Infantile OnsetMar 2027
GeneCradleGC301
AAV9 vector delivering functional human GAA gene
GAAPhase 1Pompe Disease Infantile-Onset; Pompe Disease (Late-onset)Dec 2026
AskBioAB-1009
GAA gene therapy delivered via recombinant adeno-associated virus (AAV)
GAAPhase 1Pompe Disease (Late-onset)Sep 2028
Spark TherapeuticsSPK-3006
AAV-mediated gene transfer expressing acid alpha-glucosidase (GAA)
GAAPhase 1Pompe DiseaseApr 2032
Astellaszocaglusagene nuzaparvovec (AT845)
AAV8 vector delivering functional human GAA gene under muscle-specific promoter
GAAPhase 1Pompe Disease (Late-onset)Feb 2035

Conditions

Pompe Disease (Late-onset) (4) Glycogen Storage Disease Type II (2) Pompe Disease Infantile-Onset (1) Glycogen Storage Disease Type II Infantile Onset (1) Glycogen Storage Disease Type II-Pompe's Disease (1) Glycogen Storage Disease Type II Late Onset (1) Pompe Disease (1)

Modalities

other (4), mixed (1), protein or peptide (1)

Companies

Astellas (1) GeneCradle (1) Amicus Therapeutics (1) Sanofi (1) Spark Therapeutics (1) AskBio (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.